GCP
TNGX icon

GSA Capital Partners’s Tango Therapeutics TNGX Stock Holding History

GSA Capital Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-118,593
Closed -$1.05M – 2156
2025
Q4 		$1.05M Buy
+118,593
New +$1.02M 0.09% 333
2025
Q2 		– Sell
-241,729
Closed -$331K – 2150
2025
Q1 		$331K Buy
241,729
+155,284
+180% +$381K 0.03% 1075
2024
Q4 		$267K Buy
86,445
+41,173
+91% +$191K 0.02% 1263
2024
Q3 		$349K Buy
+45,272
New +$432K 0.03% 1148
2022
Q4 		– Sell
-15,023
Closed -$54K – 1891
2022
Q3 		$54K Buy
+15,023
New +$64.2K 0.01% 1416
2022
Q2 		– Sell
-14,900
Closed -$113K – 1793
2022
Q1 		$113K Buy
+14,900
New +$129K 0.02% 1274

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

GSA Capital Partners's TNGX Position: Q1 2026 in Review

GSA Capital Partners sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 118,593 shares — an estimated $1.05M sold.

GSA Capital Partners first reported a position in TNGX in Q1 2022 and held it in 6 quarters. The position peaked at $1.05M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • GSA Capital Partners reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 118,593 Tango Therapeutics shares in Q1 2026, an estimated $1.05M.
  • GSA Capital Partners first reported a position in Tango Therapeutics in Q1 2022 and held it in 6 quarters.
  • GSA Capital Partners's Tango Therapeutics position peaked at $1.05M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.